2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12E.04 Understanding the Dynamics of TKI Induced Changes in the Tumor Immune Microenvironment for Improved Therapeutic Effect

EP.12E.04 Understanding the Dynamics of TKI Induced Changes in the Tumor Immune Microenvironment for Improved Therapeutic Effect

Back to course

Pdf Summary

The study conducted by Conghua Lu and colleagues from the Department of Respiratory Disease at Daping Hospital, Army Medical University in Chongqing, China, delves into the dynamic interplay between tyrosine kinase inhibitors (TKIs) and the tumor immune microenvironment (TME) in the context of non-small cell lung cancer (NSCLC). The research focuses on understanding how TKIs, especially those targeting EGFR and ALK mutations, affect immune components and contribute to therapeutic successes or the development of drug resistance.<br /><br />The researchers investigated the effects of both short-term and long-term TKI treatments on the TME. They observed that short-term TKI treatment leads to an enhanced T cell-mediated tumor clearance and reduction in LAMC2 protein expression, which is associated with immune evasion. However, long-term TKI treatment was found to induce an immunosuppressive environment, fostering drug resistance and immune escape.<br /><br />The study identified that ALK-targeted therapies generally provoke a stronger antitumor immune response than EGFR-targeted therapies. Furthermore, the potential role of aspirin as an adjunct therapy was explored. The results suggested that aspirin can help overcome TKI resistance by modulating the TME to boost T cell activity and tumor clearance.<br /><br />The findings underscore the importance of the TME in developing resistance to TKIs and propose that adjunct treatments such as aspirin might enhance the efficacy of TKIs. This suggests new strategies in managing NSCLC and overcoming therapeutic resistance. The research advances the understanding of TKI-induced changes in the TME, thereby providing insights into enhancing treatment outcomes for NSCLC patients.

Asset Subtitle

Conghua Lu

Meta Tag

Speaker Conghua Lu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

tyrosine kinase inhibitors

tumor immune microenvironment

non-small cell lung cancer

EGFR mutations

ALK mutations

drug resistance

immune evasion

aspirin adjunct therapy

T cell activity

therapeutic resistance